|
|
Type of Company:
Type:
|
Company
|
Ownership: |
Publicly Traded (ABUS, NASDAQ) |
Company Size: |
80 Employees In BC (80 Total)
80 In BC (80 Total)
|
Revenue: |
$21.40 Million CAD |
Year Founded: |
1992 |
Sector: |
Biotech/Life Sciences
Biotech/Life Sciences
|
Region: |
Lower Mainland / South Coast
Lower Mainland
|
Tags: |
therapeutics, development, gene silencing, RNAi, genetics
|
Profile Views: |
6,034 Company Profile Views |
|
|
|
Arbutus Biopharma Corporation is a publicly-traded (NASDAQ: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.
In addition to our HBV Assets, we are developing a pipeline of oncology, anti-viral and metabolic programs that leverage our expertise in RNA interference (RNAi) therapeutics and our Lipid Nanoparticle (LNP) technology. |
|
|
Date |
Type |
Amount |
Investors |
Date |
Type |
Amount |
Investors |
|
|
|
|
|
Apr 18, 2018
|
Arbutus Presents Complementary Results From Preclinical Combination Studies of HBV Therapeutic Candidates at EASL 2018
|
|
Apr 12, 2018
|
Arbutus and Roivant Launch Genevant Sciences with $37.5M in Seed Capital and Platform to Develop RNA Therapeutics
|
|
Feb 23, 2018
|
Arbutus Biopharma Settles Litigation, Terminating Acuitas’ Rights to LNP Technology
|
|
Feb 20, 2018
|
Arbutus Announces Departure of Chief Financial Officer; Appoints Interim CFO
|
|
Feb 16, 2018
|
Arbutus Biopharma Enters 'Exclusivity Agreement' With Roivant Sciences to Potentially Spin-Off New Company
|
|
Feb 8, 2018
|
Arbutus Biopharma to Close Burnaby Facility and Consolidates HBV Business Around Warminster, PA Site
|
|
Jan 17, 2018
|
Arbutus Announces Closing of the Second Tranche of a US $116 Million Strategic Investment from Roivant Sciences
|
|
Nov 22, 2017
|
Arbutus’ LNP Licensee Alnylam Initiates Rolling Submission of New Drug Application to U.S. FDA for Patisiran
|
|
Nov 3, 2017
|
Arbutus Announces Corporate Update and Third Quarter 2017 Financial Results
|
|
Oct 25, 2017
|
Gritstone Oncology and Arbutus Biopharma Announce LNP Technology Licensing Agreement
|
|
|
1 - 10 of 141 results
|
|
 |
|
|
|
Share This Company Profile |
|
|
|
|
|
|
Disclaimer: Company Profiles in the Tech Directory on T-Net are created, edited and maintained primarily by employees within individual companies, and are subject to continual change without notice and possible errors and/or omissions. Information within the pages of this Tech Directory is of a general nature intended only for informational purposes, and such information should not be relied upon. T-Net does not warrant or guarantee the quality, accuracy or completeness of such information and expressly disclaims liability for any loss, inconvenience or damages (including special, indirect or consequential damages) caused as a result of any errors in, or omissions from, such information. If you see an error, please let us know. Copyright T-Net. All rights reserved.
|
|
News
Events
Tech Careers
Directory
Tech Stocks
T-Net 100
Members
Feedback
About T-Net
Employers
Post Job Listings
Advertise
